Menu
Search
|

Menu

Close
X

H Lundbeck A/S LUN.CO (Copenhagen Stock Exchange)

298.90 DKK
-3.40 (-1.12%)
As of Mar 21
chart
Previous Close 302.30
Open 302.40
Volume 203,561
3m Avg Volume 419,835
Today’s High 306.20
Today’s Low 298.40
52 Week High 477.70
52 Week Low 252.30
Shares Outstanding (mil) 199.11
Market Capitalization (mil) 59,514.17
Forward P/E 15.21
Dividend (Yield %) 12.00 ( 4.01 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.41 Mean rating from 17 analysts

KEY STATS

Revenue (mm, DKK)
FY18
18,117
FY17
17,234
FY16
15,634
EPS (DKK)
FY18
19.658
FY17
13.254
FY16
6.137
*Note: Units in Millions of Danish Krone
**Note: Units in Danish Krone

KEY RATIOS

Price to Earnings (TTM)
vs sector
15.21
58.10
Price to Sales (TTM)
vs sector
3.28
8.84
Price to Book (MRQ)
vs sector
4.17
4.60
Price to Cash Flow (TTM)
vs sector
11.69
40.07
Total Debt to Equity (MRQ)
vs sector
0.51
17.66
LT Debt to Equity (MRQ)
vs sector
0.51
13.97
Return on Investment (TTM)
vs sector
27.22
12.12
Return on Equity (TTM)
vs sector
29.56
13.24

EXECUTIVE LEADERSHIP

Lars Rasmussen
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Deborah Dunsire
President, Chief Executive Officer, Interim Executive Vice President Research & Development, Since 2018
Salary: kr.3,400,000.00
Bonus: kr.3,300,000.00
Lene Skole-Soerensen
Deputy Chairman of the Board, Since 2015
Salary: --
Bonus: --
Anders Goetzsche
Chief Financial Officer, Executive Vice President, Since 2018
Salary: kr.5,900,000.00
Bonus: kr.3,800,000.00
Peter Anastasiou
Executive Vice President, North America, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Ottiliavej 9
VALBY     2500

Phone:

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

SPONSORED STORIES